Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study.

Purpose: There is emerging evidence that germline pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes (CPGs) increase the risk of subsequent neoplasms (SNs) in childhood cancer survivors. However, clinical application of this observation is hampered by the lack of knowledge regarding subpopulations at risk for SNs who could potentially benefit from genetic screening.

Patients And Methods: Whole-exome sequencing was performed using germline DNA from 499 survivors with SNs (cases) and 625 survivors without (matched controls) in a Children's Oncology Group study.

Childhood Cancer Data Initiative: Expanded access to tumor molecular profiling for children, adolescents, and young adults.

The Molecular Characterization Initiative (MCI), a key effort of the NCI's Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children's Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. De-identified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies.

The potential mediating role of depression on medical mistrust and mental health service use in Black adults.

Background: Major depressive disorders are ranked third in the global burden of disease by the World Health Organization. The association between mistrust in Black adults and its effect on health service utilization is well established. However, research on mistrust and specific utilization of mental health services is limited.

Gaps and uncertainties in the management of acute pancreatitis: a scoping review and quality assessment of clinical practice guidelines.

Background: Universal health coverage (UHC) emphasises equitable care for all, without financial hardships and healthcare professionals use clinical practice guidelines (CPGs) to inform service delivery. With rising burden of acute pancreatitis worldwide, the recent James Lind Alliance highlighted knowledge gaps exist within current pathways. This scoping review and quality assessment aims to determine gaps and uncertainties in CPGs for the management of acute pancreatitis.

Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration.

The twelfth multi-stakeholder Paediatric Strategy focused on cyclin-dependent kinase (CDK) inhibitors. Genetic aberrations in paediatric tumours increase CDK4/6 activity, thus the pathway is a therapeutic target. As a result, CDK4/6 inhibitors have been evaluated in clinical trials for children and young adults with different malignancies, both as single agents and in combination, including molecular enrichment in ESMART.